237 related articles for article (PubMed ID: 21533169)
1. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.
Proia DA; Foley KP; Korbut T; Sang J; Smith D; Bates RC; Liu Y; Rosenberg AF; Zhou D; Koya K; Barsoum J; Blackman RK
PLoS One; 2011 Apr; 6(4):e18552. PubMed ID: 21533169
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
3. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
[TBL] [Abstract][Full Text] [Related]
4. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
5. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Shimamura T; Perera SA; Foley KP; Sang J; Rodig SJ; Inoue T; Chen L; Li D; Carretero J; Li YC; Sinha P; Carey CD; Borgman CL; Jimenez JP; Meyerson M; Ying W; Barsoum J; Wong KK; Shapiro GI
Clin Cancer Res; 2012 Sep; 18(18):4973-85. PubMed ID: 22806877
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
Friedland JC; Smith DL; Sang J; Acquaviva J; He S; Zhang C; Proia DA
Invest New Drugs; 2014 Feb; 32(1):14-24. PubMed ID: 23686707
[TBL] [Abstract][Full Text] [Related]
7. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF
Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996
[TBL] [Abstract][Full Text] [Related]
9. A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.
Bareng J; Jilani I; Gorre M; Kantarjian H; Giles F; Hannah A; Albitar M
Leuk Lymphoma; 2007 Nov; 48(11):2189-95. PubMed ID: 17926180
[TBL] [Abstract][Full Text] [Related]
10. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
11. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Koppikar P; Bhagwat N; Kilpivaara O; Manshouri T; Adli M; Hricik T; Liu F; Saunders LM; Mullally A; Abdel-Wahab O; Leung L; Weinstein A; Marubayashi S; Goel A; Gönen M; Estrov Z; Ebert BL; Chiosis G; Nimer SD; Bernstein BE; Verstovsek S; Levine RL
Nature; 2012 Sep; 489(7414):155-9. PubMed ID: 22820254
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models.
Lin SF; Lin JD; Hsueh C; Chou TC; Yeh CN; Chen MH; Wong RJ
Oncotarget; 2017 Jun; 8(25):41294-41304. PubMed ID: 28476040
[TBL] [Abstract][Full Text] [Related]
13. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.
Lock RB; Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 Jul; 60(7):E42-5. PubMed ID: 23303741
[TBL] [Abstract][Full Text] [Related]
14. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
Liu H; Lu J; Hua Y; Zhang P; Liang Z; Ruan L; Lian C; Shi H; Chen K; Tu Z
Cell Death Dis; 2015 Jan; 6(1):e1595. PubMed ID: 25590805
[TBL] [Abstract][Full Text] [Related]
15. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
He S; Smith DL; Sequeira M; Sang J; Bates RC; Proia DA
Invest New Drugs; 2014 Aug; 32(4):577-86. PubMed ID: 24682747
[TBL] [Abstract][Full Text] [Related]
16. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X
Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218
[TBL] [Abstract][Full Text] [Related]
17. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
[TBL] [Abstract][Full Text] [Related]
18. Recent updates on the development of ganetespib as a Hsp90 inhibitor.
Choi HK; Lee K
Arch Pharm Res; 2012 Nov; 35(11):1855-9. PubMed ID: 23212626
[TBL] [Abstract][Full Text] [Related]
19. Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling.
Lee H; Saini N; Parris AB; Zhao M; Yang X
Int J Oncol; 2017 Sep; 51(3):967-974. PubMed ID: 28713919
[TBL] [Abstract][Full Text] [Related]
20. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
Weigert O; Lane AA; Bird L; Kopp N; Chapuy B; van Bodegom D; Toms AV; Marubayashi S; Christie AL; McKeown M; Paranal RM; Bradner JE; Yoda A; Gaul C; Vangrevelinghe E; Romanet V; Murakami M; Tiedt R; Ebel N; Evrot E; De Pover A; Régnier CH; Erdmann D; Hofmann F; Eck MJ; Sallan SE; Levine RL; Kung AL; Baffert F; Radimerski T; Weinstock DM
J Exp Med; 2012 Feb; 209(2):259-73. PubMed ID: 22271575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]